BIXT Stock — Bioxytran Inc

Bioxytran Inc (BIXT)

Updated October 14, 2026.

BIXT is a Stock. Its deepest 1-year drawdown was 77.7%.

Bioxytran is a clinical-stage pharmaceutical company developing therapeutic drugs for viral infections, oxygen delivery, and degenerative diseases. Its lead candidate, BXT-25, is an oxygen-carrying molecule designed to treat hypoxic conditions in stroke and wound healing, while a secondary program, ProLectin, targets mild to moderate COVID-19. The company does not currently distribute to shareholders.

BIXT performance

Returns are updating. BIXT's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 77.7%.

BIXT key facts

Asset type

Stock

Asset class

Equity

Inception date

01/05/2010

Distribution frequency

None

Last close

$0.02 (stale; as of 2026-10-14)

Market cap

$2,637,990

Average volume

21000.0

Payment date

08/22/2018

Beta

2.315

Payout ratio

0.0%

EPS

$-0.02

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BIXT risks and drawbacks

The deepest 1-year drawdown on record here is 77.7%.

Who may consider BIXT — and who may not

It is a weaker fit for investors who need monthly cash flow (BIXT does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on BIXT

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions